Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

MTSR

Metsera Inc

Feb 11 • 04:00PM ET

30.76

Dollar change +0.68
Percentage change 2.26	%

Healthcare • Biotechnology • USA • NASD

Held by: ONEQ BMED

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	38.63%	Shs Outstand	103.04M	Perf Week	9.82%
Market Cap	3.17B	Forward P/E	-	EPS next Y	-	Insider Trans	15.14%	Shs Float	63.23M	Perf Month	-
Income	-	PEG	-	EPS next Q	-	Inst Own	1.80%	Short Float	-	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	29.10%	Short Ratio	-	Perf Half Y	-
Book/sh	-0.44	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf Year	-
Cash/sh	0.73	P/C	42.15	EPS next 5Y	-	ROE	-	52W Range	25.06 - 31.64	Perf YTD	16.08%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-2.78%	Beta	-
Dividend TTM	-	Quick Ratio	3.81	Sales past 5Y	0.00%	Gross Margin	-	52W Low	22.75%	ATR (14)	2.39
Dividend Ex-Date	-	Current Ratio	3.81	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	-	Volatility	6.34% -
Employees	-	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-	Payout	-	Rel Volume	0.12	Prev Close	30.08
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	1.38M	Price	30.76
SMA20	6.33%	SMA50	6.33%	SMA200	6.33%	Trades		Volume	166,935	Change	2.26%

Feb-05-25 04:01PM	Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-30-25 08:13PM	Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs (Bloomberg)
06:53PM	Metsera Announces Pricing of Initial Public Offering (GlobeNewswire)
02:57PM	Metsera, Maze secure combined $415 million in IPOs (BioPharma Dive)

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burow Kristina	Director	Feb 03 '25	Buy	18.00	2,222,222	39,999,996	18,503,128	Feb 03 07:15 PM
BERNS PAUL L	Director	Feb 03 '25	Buy	18.00	789,998	14,219,964	8,313,680	Feb 03 07:04 PM
ARCH Venture Partners XII, LLC	10% Owner	Feb 03 '25	Buy	18.00	2,222,222	39,999,996	18,503,128	Feb 03 07:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MTSR

Metsera Inc

Upgrade your FINVIZ experience